INVO Fertility (IVF) Shares Slide -44% Over 30 Days as Persistent Pressures Mount
Key Takeaways
- INVO Fertility (IVF) shares fell roughly 44% over the trailing 30 days, sliding from about $1.02 to $0.57.
- The decline extends a much longer downtrend: the stock is down approximately 98% over the past 52 weeks and trades near its 52-week low.
- Shares remain below both the 50-day and 200-day moving averages, with a relative strength index near 25 pointing to deeply oversold conditions.
- Persistent net losses, negative operating cash flow, and a recent increase in shares outstanding have weighed on investor sentiment.
- As a micro-cap with a market value near $2.7 million and a beta of roughly 1.4, the stock remains prone to sharp, outsized swings.
- For additional context, explore INVO Fertility's Price Targets, Earnings, and Forecast.
- Discover how automated strategies approach this and other names on the Trending AI Robots page.
INVO Fertility (IVF) Business Snapshot
INVO Fertility, Inc. operates in the fertility services space. Formerly known as NAYA Biosciences, the company runs two main segments: fertility clinic services and its proprietary INVOcell device. The INVOcell technology allows fertilization and early embryo development inside the patient's body via an intravaginal culture procedure, offering what the company positions as a more accessible and lower-cost option compared with traditional in-vitro fertilization.
In addition to the device, INVO Fertility acquires and operates fertility clinics, including its INVO Centers, and licenses the INVOcell technology to other providers. The stock draws interest from investors focused on the expanding assisted reproductive technology sector and the company's acquisition-driven growth plan aimed at reaching cash-flow breakeven.
Recent Price Action: 30-Day and Quarterly Moves
Over the past 30 days, IVF declined approximately 44%, moving from a closing level near $1.02 down to roughly $0.57. The drop unfolded through a series of lower highs and lower lows rather than a single sharp event, with selling intensifying in the first half of October. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The quarterly picture looks comparable. From late July through late October the shares also fell about 44%. A brief high-volume spike on August 17 pushed the stock as high as $2.80 intraday, but those gains were quickly reversed. That failed move marked the start of a renewed decline that has carried the price steadily lower toward its 52-week low.
Key Factors Behind the Latest 30-Day Decline
The recent weakness stems from a mix of fundamental and technical factors rather than any single catalyst. With a market capitalization near $2.7 million, IVF remains sensitive to liquidity shifts and sentiment changes, and its beta of roughly 1.4 highlights above-average volatility.
On the fundamentals side, the company continues posting net losses and negative operating cash flow. Shares outstanding rose sharply quarter-over-quarter, which has raised dilution concerns. A current ratio below 1.0 also points to a relatively constrained liquidity position. Technically, the stock has moved below both its 50-day and 200-day moving averages and sits in deeply oversold territory, yet sustained buying interest has not materialized.
Quarterly Drivers and Strategic Context
Over the quarter, the story has centered on a small-cap growth name struggling to maintain investor confidence. The August spike and subsequent reversal show how quickly speculative interest can fade in a thinly traded stock, after which the downtrend resumed.
The broader backdrop includes the company's shift toward a pure-play fertility model. INVO Fertility divested a majority stake in its former oncology business and has pursued acquisitions of U.S. clinics. While management continues to target cash-flow breakeven, ongoing losses and the funding needs tied to those acquisitions have kept pressure on the share price.
Factors to Monitor Going Forward
Several items will likely influence the stock's path from here. The next earnings report is due in mid-November, and investors will focus on revenue trends, progress in narrowing losses, and any updates on the cash-flow breakeven timeline. Developments around clinic acquisitions and the pace of share issuance will also draw attention given their direct effect on this small equity base.
Broader industry and macroeconomic trends in fertility care demand, along with any regulatory shifts in assisted reproductive technology, could sway sentiment as well. Trading at a fraction of its 52-week high and in oversold territory, any signs of fundamental stabilization or renewed institutional interest could carry extra weight. Micro-cap investing carries elevated risk, and outcomes remain uncertain.
Using AI Tools for Market Monitoring
From what I see, Tickeron's Trending AI Robots page offers a useful way to review top-performing automated trading bots across different strategies and timeframes. While the platform runs hundreds of AI-driven bots on thousands of tickers, this curated section surfaces the most relevant and highest-performing ones. For volatile micro-cap names like IVF, these tools can help track momentum and pattern-based signals without relying on a single approach. I find it helpful to cross-check ideas here alongside my own analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for IVF turns negative, indicating new downward trend
IVF saw its Momentum Indicator move below the 0 level on September 24, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned negative. In 78 of the 81 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for IVF turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 41 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IVF entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVF advanced for three days, in 157 of 191 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
IVF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.089) is normal, around the industry mean (2.914). P/E Ratio (0.000) is within average values for comparable stocks, (1.904). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.130) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. IVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement